An economic model comparing different types of genetic testing in metastatic non-small cell lung cancer showed that next-generation sequencing is more cost-effective than testing for one or a limited number of genes at a given time.
non-small cell lung cancer
A new study found that timely reporting of palliative care needs may lead to less aggressive therapy and end-of-life care among patients with non-small cell lung cancer.
A study presented at the European Lung Cancer Congress investigated the effects of multiple therapies on symptom management in ALK-positive non-small cell lung cancer.
Does First-Line Targeted Therapy Plus Immunotherapy Produce Durable Responses in ALK-Positive NSCLC?
A recent study assessed whether combining a targeted therapy with an immunotherapy for ALK translocation-positive advanced non-small cell lung cancer results in more durable patient responses.
Health care resource use and approaches to clinical management of advanced non-small cell lung cancer vary significantly in eight different countries.
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
The National Comprehensive Cancer Network modified their guidelines for both non-small cell lung cancer and lung cancer screening to reflect new staging designations and testing results.
Immunotherapy treatment past progression for patients with advanced lung cancer may account for 29% of total treatment costs, without clear value for most patients, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.